| Drug Name |
Vesicare |
| Drug ID |
BADD_D02353 |
| Description |
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511]
Solifenacin was granted FDA approval on 19 November 2004.[L7511] |
| Indications and Usage |
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] |
| Marketing Status |
approved |
| ATC Code |
G04BD08 |
| DrugBank ID |
DB01591
|
| KEGG ID |
D01269
|
| MeSH ID |
D000069464
|
| PubChem ID |
154058
|
| TTD Drug ID |
D0L4YD
|
| NDC Product Code |
70771-1604; 47621-301; 65977-0042; 68382-987; 68382-988; 70771-1605 |
| UNII |
A8910SQJ1U
|
| Synonyms |
Solifenacin Succinate | Succinate, Solifenacin | Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate | YM905 | YM 905 | 905, YM | Vesicare | Solifenacin | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))- |
